Drug Database
DE

dexamethasone (OT502 / IBI10090 / OT 502)

✓ Approved

Ocumension Therapeutics Co., Ltd. · NR3C1 · Steroids

What is dexamethasone?

dexamethasone is a steroids developed by Ocumension Therapeutics Co., Ltd.. It is approved for therapeutic indications via injectable (others) or intraocular injection.

Drug Profile

Brand NamesOT502, IBI10090, OT 502
CompanyOcumension Therapeutics Co., Ltd.
Drug ClassSteroids, Small Molecule
Molecular TargetNR3C1
RouteInjectable (Others), Intraocular Injection
StatusApproved

Mechanism of Action

Molecular Targets

dexamethasone acts on 1 molecular target:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

dexamethasone is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Eye disordersCataract✓ Approved

Related Research Articles

PubMedCells2026-10-16

Dexamethasone Modulates Global DNA Methylation and Oxidative DNA Damage in Glioblastoma Cell Lines.

Barciszewska Anna-Maria AM, Belter Agnieszka A, Barciszewski Jakub F JF, Perrigue Patrick M PM et al.

Glioblastoma remains one of the most aggressive primary brain tumors, characterized by rapid progression, therapeutic resistance, and poor prognosis. Dexamethasone is routinely administered to patients with glioblastoma to reduce peritumoral edema and improve neurological symptoms. However, its broader molecular effects on tumor-cell biology and treatment response remain incompletely understood. This study examined the effects of dexamethasone alone and in combination with temozolomide, valproic acid, or metformin on glioblastoma cell viability, real-time proliferation, senescence-associated β-galactosidase activity, cell-cycle distribution, global DNA methylation, and oxidative DNA damage. Dexamethasone induced concentration- and time-dependent changes in global DNA methylation in glioma cells. In T98G cells, shorter exposure increased 5-methylcytosine, whereas longer incubation or selected combined treatment conditions reduced methylation, suggesting dynamic epigenetic remodeling. Low dexamethasone concentrations were associated with increased 5-methylcytosine content, also in temozolomide-containing conditions. In contrast, higher dexamethasone concentrations reduced global methylation. That effect was cell-line dependent. In SW1783 cells, high-dose dexamethasone caused a reduction in 5-methylcytosine amount as well as an increase in 8-oxo-2'-deoxyguanosine level. Dexamethasone also reduced real-time T98G cell proliferation after prolonged exposure, while temozolomide was the main compound associated with cell-cycle changes in T98G cells. Metformin displayed comparatively limited cytotoxicity under the tested conditions. Beyond dexamethasone's well-established anti-edematous and anti-inflammatory role, it may also modify glioma redox and epigenetic states and influence cellular responses to temozolomide, valproic acid, and metformin. When considering these findings it is necessary to take into account a number of limitations. The upper limits of the DEX, TMZ, and MF concentration ranges were one to three orders of magnitude higher than the brain or CSF exposure levels that have been reported, and the experiments were carried out at standard culture oxygen concentrations (about 18-21% O2), which are much higher than the oxygen levels found in brain tissue (about 2-6% O2). Furthermore, the conclusions drawn from the T98G experiments only apply to this cell line and cannot be applied to glioblastoma without first being verified in other models.

PubMedInternational journal of molecular sciences2026-10-16

Gamma-Oryzanol Solid Dispersion Attenuates Dexamethasone-Induced Depressive-like Behaviors in Rats Associated with Calbindin-1 and Calcium Signaling.

Kesyou Siripaporn S, Tiyaboonchai Waree W, Roboon Jureepon J, Kaewman Paweena P et al.

Depression is associated with dysfunction of the hypothalamic-pituitary-adrenal axis, neurotransmitter imbalance, and calcium signaling deficits. Although gamma-oryzanol (GO) has shown antidepressant effects, its underlying molecular mechanism remains elusive, while its poor aqueous solubility limits its nutraceutical application. To overcome this obstacle, we successfully developed GO solid dispersion (GOSD) with enhanced water solubility for nutraceutical formulations. This study examined the antidepressant effect of GOSD in dexamethasone (Dx)-induced depressive-like behaviors in rats using behavioral tests, including the sucrose preference test and forced-swimming test (FST). The Dx group showed a reduction in sucrose consumption and mobility time in the FST compared with controls, both of which improved following GOSD administration. Proteomics revealed changes associated with the calcium signaling pathway. Calbindin (Calb1) expression was reduced in the Dx group, whereas GOSD administration restored Calb1 levels. Given the role of Calb1, a calcium-binding protein (CBP) involved in intracellular calcium buffering, reduced Calb1 expression in the Dx group may contribute to calcium signaling dysregulation. In contrast, GOSD can attenuate Calb1 levels, which potentially contribute to its antidepressant effects. These findings suggest that the antidepressant-like effects of GOSD may involve modulation of calcium homeostasis, supporting its potential as a complementary intervention for Dx-induced depressive-like behaviors.

PubMedVestnik oftalmologii2026-10-16

[Functional and anatomical outcomes of various perioperative treatment strategies for diabetic macular edema after cataract phacoemulsification].

Fursova A Zh AZ, Vasilyeva M A MA, Derbeneva A S AS, Karlash Yu A YA et al.

Selecting the optimal perioperative treatment strategy for diabetic macular edema (DME) in patients undergoing cataract phacoemulsification remains an important clinical challenge. The effects of different approaches on changes in morphological OCT biomarkers remain insufficiently studied. The study aimed to compare the functional and anatomical outcomes of three perioperative strategies for DME treatment after cataract phacoemulsification. This retrospective cohort study included 102 patients (102 eyes) with type 2 diabetes mellitus, DME, and cataract. In group 1 (n=42), patients received preoperative anti-VEGF therapy followed by treatment according to the Treat-and-Extend regimen, group 2 (n=29) in addition to the same anti-VEGF regimen underwent intraoperative dexamethasone implantation, and group 3 (n=31) first underwent intraoperative dexamethasone implantation and then received anti-VEGF therapy. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), fluid OCT biomarkers, hyperreflective foci, and the inter-injection interval were assessed. BCVA improved significantly in all groups by month 12 of follow-up (from 0.22±0.12 to 0.64±0.17; p<0.001). The combined strategy provided the earliest reduction in CRT and CCT, rapid resolution of intraretinal and subretinal fluid, a decrease in the number of hyperreflective foci, and prolongation of the inter-injection interval. With the DEX-first strategy, after a pronounced early effect, by month 6 DME had reactivated with loss of anatomical response. Despite comparable functional outcomes at 12 months, the perioperative strategies differed substantially in the speed of achieving and maintaining anatomical response. The combined strategy provided the most favorable trajectory of morphological response and the most effective control of the inflammatory and exudative activity of DME in the early postoperative period.

PubMedJournal of pharmacokinetics and pharmacodynamics2026-10-16

Modified frequency-based sensitivity analysis for oscillatory system models.

Ma Xinyue X, Mager Donald E DE

Global sensitivity analysis (GSA) is a critical and widely used method for evaluating model performance, as it quantifies input variability and uncertainty in both linear and nonlinear systems, with or without parameter interactions. However, for quantitative systems pharmacology or systems biology models with complex dynamics and time-dependent output exhibiting a single dominant oscillatory frequency, the classic GSA computed on fixed-time outputs may overlook parameters controlling oscillatory behaviors. To address this, a Fourier-based approach was refined to extract a single dominant oscillatory frequency across model simulated temporal profiles and define them as the quantity of interest (QoI) to compute the Sobol indices. Surrogate modeling was used to improve computational efficiency, which reduced computation time by at least 10-fold while recovering the ranking of influential parameters. This methodology was applied to several cases, including one involving dexamethasone treatment, to showcase how drug-induced perturbations can alter parameter sensitivity. In conclusion, these cases demonstrate the utility and efficiency of a Fourier-based GSA for identifying parameters controlling a dominant frequency in oscillatory system models.

PubMedInternational journal of molecular sciences2026-10-16

Knock-Down of Glucocorticoid Receptor Beta (GRβ) Enhances the Ocular Hypertensive Response to Dexamethasone in C57BL/6J Mice.

Millar J Cameron JC, Patel Pinkal D PD, Clark Abbot F AF

Topical ocular treatment with glucocorticoids (GCs) yields an increase in intraocular pressure (IOP) in a subset (~35-40%) of the human population, known as steroid responders. If treatment is continued, this ocular hypertension (OHT) can develop into GC-induced glaucoma. In mice, the GC-mediated OHT response is modulated by the GC receptor, which exists as two major splice variants, GRα and GRβ, in the TM cell cytosol. GRα contains a GC-binding domain. Following GC binding, the GRα-GC complex enters the TM cell nucleus and transactivates genes associated with increased synthesis/export of extracellular matrix (ECM), causing OHT. GRβ has no ligand-binding domain but appears to inhibit gene transactivation by the GRα-GC complex. We previously described the effects of over-expression of GRβ on the GC-induced OHT response on IOP in mice. Here, we investigated the effect of the GC Dexamethasone (DEX) on the OHT response in C57BL/6J mice, under conditions of GRβ knockdown. A total of 20 × C57BL/6J mice (♀), aged 3-4½ months were used. Animals were weighed. Baseline (BL) conscious IOP measurements (TonoLab) and direct ophthalmoscopy (Keeler Instruments Specialist Model Ophthalmoscope) assessments were made. Animals were divided into 4 cohorts (n = 5/cohort), and anesthetized (isoflurane (2.5%) and O2(g) (0.8 L/min)). Cohorts 1 and 2 (n = 10 animals) were given an intravitreal (IVT) injection in both eyes (OU) of Lenti.shRNA.Scramble (2.2 × 109 TU/mL; 1 μL bolus injection (total 2.2 × 106 TU/eye)). Cohorts 3 and 4 (n = 10 animals) were given an IVT injection OU of Lenti.shRNA.GRβ (1.09 × 109 TU/mL; 2 μL bolus injection (total 2.18 × 106 TU/eye)). Each subsequent week, for 8 weeks, conscious IOPs were measured (OU), and direct ophthalmoscopy was performed. Animals were then anesthetized and given a periocular injection OU of a 20 μL bolus (per eye) of either vehicle solution for DEX (DEX-Veh) (Cohorts 1 (n = 5 animals) and 3 (n = 5 animals), or micronized DEX suspension (Cohorts 2 (n = 5 animals) and 4 (n = 5 animals)). At the conclusion of the study, animals were euthanized and TM tissues were collected (OD and OS pooled per animal) for assay of GRβ mRNA expression using QPCR. GRβ mRNA expression in the TM was significantly reduced by greater than 95% in the Lenti.shRNA.GRβ group vs. the Lenti.shRNA.Scramble group (p < 0.0001). Injection of Lenti.shRNA.Scramble or Lenti.shRNA.GRβ had no effect on baseline IOP. Subsequent injections of DEX over the following 8 weeks led to a significant increase in mean IOP in both groups (baseline 12.5 mmHg; 23 mmHg in Lenti.shRNA.Scramble cohort (p < 0.0001); and 28 mmHg in Lenti.shRNA.GRβ cohort (p < 0.0001)). DEX-induced IOP was significantly higher in the shRNA.GRβ cohort compared to the shRNA.Scramble cohort (p < 0.0001). Animals given vehicle control did not show an increase in IOP. Eyes that received DEX had very mild lenticular cataracts at Week 8, but there was no significant reduction in body weight. GRβ plays a role in modulating the IOP response to DEX in C57BL/6J mice. Knockdown of endogenous mRNA encoding GRβ results in an enhanced IOP response to DEX.

PubMedJournal of clinical medicine2026-10-16

Severe Hypercalcemia and Acute Kidney Injury in a Patient with Probable IgG4-Related Disease and Cholestatic Liver Injury: A Case Report.

Chang Chi-Hsien CH, Tsai Shang-Feng SF

We report a 54-year-old man with a history of urticaria, hyperlipidemia, and hypertension who was receiving regular bisoprolol, rosuvastatin, and verapamil. He initially developed severe hypercalcemia (18.56 mg/dL) and acute kidney injury (serum creatinine, 5.14 mg/dL) while in China. Following intravenous hydration and calcitonin, serum calcium normalized and renal function substantially improved. During hospitalization, he subsequently developed marked eosinophilia, severe thrombocytopenia, cholestatic liver injury, lymphadenopathy, and markedly elevated serum IgG4 (851 mg/dL). Extensive evaluation did not identify evidence of malignancy or infection. The overall findings raised clinical suspicion of IgG4-related disease (IgG4-RD) with possible hepatobiliary involvement and suspected immune-mediated thrombocytopenia. Ursodeoxycholic acid and fenofibrate were initiated when primary biliary cholangitis remained under consideration, followed by systemic corticosteroid therapy with dexamethasone. The patient's liver abnormalities, thrombocytopenia, eosinophilia, and systemic manifestations subsequently improved. However, definitive tissue confirmation of IgG4-RD was not obtained, and characteristic cholangiographic evidence of IgG4-related sclerosing cholangitis was unavailable because MRCP or ERCP was not performed. During six months of outpatient follow-up, renal function remained stable and no clinical or biochemical relapse was observed. This case highlights severe hypercalcemia and acute kidney injury as unusual presenting features in a patient with clinical suspicion of IgG4-RD and emphasizes the importance of cautious diagnostic interpretation when histopathological and cholangiographic confirmation is unavailable.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about dexamethasone